QQQ   357.47 (-0.15%)
AAPL   170.79 (+0.06%)
MSFT   315.77 (+0.68%)
META   300.54 (-1.13%)
GOOGL   130.72 (-1.20%)
AMZN   126.88 (+0.71%)
TSLA   247.24 (+0.35%)
NVDA   433.74 (+0.66%)
NIO   8.94 (+0.34%)
BABA   86.69 (+1.34%)
AMD   102.97 (+0.20%)
T   14.96 (-0.33%)
F   12.36 (-1.59%)
MU   67.74 (+3.90%)
CGC   0.78 (-3.69%)
GE   110.02 (-2.07%)
DIS   80.45 (+0.40%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.19 (+0.02%)
NFLX   375.89 (-0.12%)
QQQ   357.47 (-0.15%)
AAPL   170.79 (+0.06%)
MSFT   315.77 (+0.68%)
META   300.54 (-1.13%)
GOOGL   130.72 (-1.20%)
AMZN   126.88 (+0.71%)
TSLA   247.24 (+0.35%)
NVDA   433.74 (+0.66%)
NIO   8.94 (+0.34%)
BABA   86.69 (+1.34%)
AMD   102.97 (+0.20%)
T   14.96 (-0.33%)
F   12.36 (-1.59%)
MU   67.74 (+3.90%)
CGC   0.78 (-3.69%)
GE   110.02 (-2.07%)
DIS   80.45 (+0.40%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.19 (+0.02%)
NFLX   375.89 (-0.12%)
QQQ   357.47 (-0.15%)
AAPL   170.79 (+0.06%)
MSFT   315.77 (+0.68%)
META   300.54 (-1.13%)
GOOGL   130.72 (-1.20%)
AMZN   126.88 (+0.71%)
TSLA   247.24 (+0.35%)
NVDA   433.74 (+0.66%)
NIO   8.94 (+0.34%)
BABA   86.69 (+1.34%)
AMD   102.97 (+0.20%)
T   14.96 (-0.33%)
F   12.36 (-1.59%)
MU   67.74 (+3.90%)
CGC   0.78 (-3.69%)
GE   110.02 (-2.07%)
DIS   80.45 (+0.40%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.19 (+0.02%)
NFLX   375.89 (-0.12%)
QQQ   357.47 (-0.15%)
AAPL   170.79 (+0.06%)
MSFT   315.77 (+0.68%)
META   300.54 (-1.13%)
GOOGL   130.72 (-1.20%)
AMZN   126.88 (+0.71%)
TSLA   247.24 (+0.35%)
NVDA   433.74 (+0.66%)
NIO   8.94 (+0.34%)
BABA   86.69 (+1.34%)
AMD   102.97 (+0.20%)
T   14.96 (-0.33%)
F   12.36 (-1.59%)
MU   67.74 (+3.90%)
CGC   0.78 (-3.69%)
GE   110.02 (-2.07%)
DIS   80.45 (+0.40%)
AMC   7.93 (+1.80%)
PFE   33.13 (+3.24%)
PYPL   58.19 (+0.02%)
NFLX   375.89 (-0.12%)
NYSE:NAVB

Navidea Biopharmaceuticals (NAVB) Stock Forecast, Price & News

$0.09
0.00 (-3.54%)
(As of 01:57 PM ET)
Compare
Today's Range
$0.09
$0.10
50-Day Range
$0.07
$0.12
52-Week Range
$0.06
$0.35
Volume
1.38 million shs
Average Volume
3.71 million shs
Market Capitalization
$8.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NAVB stock logo

About Navidea Biopharmaceuticals (NYSE:NAVB) Stock

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

NAVB Price History

NAVB Stock News Headlines

Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Q4 2022 Navidea Biopharmaceuticals Inc Earnings Call
See More Headlines
Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Company Calendar

Last Earnings
8/11/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Employees
11
Year Founded
N/A

Profitability

Net Income
$-15,180,000.00
Pretax Margin
-134,000.00%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
($0.25) per share

Miscellaneous

Free Float
54,546,000
Market Cap
$9.32 million
Optionable
Optionable
Beta
1.54
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Craig A. Dais CPA (Age 57)
    Chief Financial Officer & Principal Accounting Officer
  • Dr. Michael Sherman Blue F.A.C.E.P.
    M.D., Chief Medical Officer













NAVB Stock - Frequently Asked Questions

How have NAVB shares performed in 2023?

Navidea Biopharmaceuticals' stock was trading at $0.21 at the start of the year. Since then, NAVB shares have decreased by 55.7% and is now trading at $0.0931.
View the best growth stocks for 2023 here
.

When is Navidea Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our NAVB earnings forecast
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) posted its earnings results on Friday, August, 11th. The company reported ($0.03) earnings per share for the quarter.

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.09.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals (NYSE:NAVB) has a market capitalization of $9.32 million and generates $70,000.00 in revenue each year. The company earns $-15,180,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Avenue, Suite 240, Dublin, OH 43017-3552, United States. The official website for the company is www.navidea.com. The company can be reached via phone at 614-793-7500, via email at jkaufman@navidea.com, or via fax at 614-793-7522.

This page (NYSE:NAVB) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -